Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Nair, Rahul ^a   Kumar, Ashok Ck ^a   Priya, Vishnu K ^a   Yadav, Chakrapani M ^a   Raju, Prasanna Y ^a  

^a Prince Dr K Vasudevan College of Engineering and Technology   (India)

Author keywords

Carbamazepine; Chitosan; Encapsulation efficiency; Solid lipid nanoparticles

Indexed keywords

ALCOHOL; CARBAMAZEPINE; CHITOSAN; ORGANIC SOLVENT; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; EPILEPSY; HYDRODYNAMICS; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NANOENCAPSULATION; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SUSPENSION; ZETA POTENTIAL;

ANIMALS; ANTICONVULSANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; ELECTRIC STIMULATION; MALE; NANOCAPSULES; PARTICLE SIZE; RATS; RATS, WISTAR; SEIZURES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRIGLYCERIDES;

EID: 84862223919     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-72     Document Type: Article

References (23)

1. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Zur Muhlen A, Schwarz C, Mehnert W, Eur J Pharm Biopharm 1998 45 2 149 155 10.1016/S0939-6411(97)00150-1 9704911 (Pubitemid 28167741)
2. Solid lipospheres of doxorubicin and idarubicin. Cavalli R, Caputo O, Gasco MR, Int J Pharm 1993 89 1 9 R12 10.1016/0378-5173(93)90313-5 (Pubitemid 23008586)
3. Spray-drying of Solid lipid nanoparticles (SLNTM). Freitas C, Müller RH, Eur J Pharm Biopharm 1998 46 2 145 151 10.1016/S0939-6411(97)00172-0 9795036 (Pubitemid 28414472)
4. Liposphere parenteral delivery system. Domb AJ, Proc Intl Symp Control Rel Bioact Mater 1993 20 346 347
5. Zur Muhlen A, Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilitat, Charakterisierung, Freisetzungsverhalten and mechanismen. Ph.D. thesis Free University of Berlin 1996
6. Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy. Eldem T, Speiser P, Hincal A, Pharm Res 1991 8 47 54 10.1023/A:1015874121860 2014208
7. Cytotoxicity of magnetite-loaded polylactide, polylactide/ glycolide particles and solid lipid nanoparticles. Muller RH, Maabenb S, Weyhersa H, Spechtb F, Lucksb JS, Int J Pharm 1996 138 1 85 94 10.1016/0378-5173(96)04539-5 (Pubitemid 26241925)
8. Speiser P, Lipidnanopellets als Tragersystem fur Arzneimittel zur perolen Anwendung 1990 European Patent, EP 0167825
9. Solid lipid nanoparticles: production, characterization and applications. Mehnert W, Mäder K, Adv Drug Deliver Rev 2001 47 2-3 165 196 (Pubitemid 32324113)
10. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) - effect of surfactants, storage time and crystallinity. Muller RH, Olbrich C, Kayser O, Int J Pharm 2002 237 119 128 10.1016/S0378-5173(02)00035-2 11955810 (Pubitemid 34310485)
11. Solid lipid nanoparticle (SLN) for controlled drug delivery-review of the state of the art. Muller RH, Maader K, Gohla S, Eur J Pharm Biopharm 2000 50 161 177 10.1016/S0939-6411(00)00087-4 10840199 (Pubitemid 30326695)
12. Solid lipid nanoparticles (SLN) for controlled drug delivery. Muller RH, Runge SA, Submicron Emulsions in Drug Targeting and Delivery Amsterdam: Harwood Academic Publishers, Benita S, 1998 219 234
13. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Jenning V, Gysler A, Schafer-Korting M, Gohla S, Eur J Pharm Biopharm 2000 49 3 211 218 10.1016/S0939-6411(99)00075-2 10799811 (Pubitemid 30229868)
14. Katja H, Andreas H, Reinhard S, Chitosan-based transport system 2005 US 2006/0051423 A1
15. Foreman JC, Johansen T, Textbook of Receptor Pharmacology Boca Raton, FL: CRC Press 2 2002
16. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Ridolfia DM, Marcatoa PD, Justob GZ, Cordid L, Machadob D, Duran N, Colloids Surf B Biointerfaces 2012 93 1 36 40 22244299
17. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Safal J, Sanjay J, Piush K, Arvind G, Divya BL, Sanjay KJ, Drug Delivery 2010 17 6 443 451 10.3109/10717544.2010.483252 20486871
18. Solid lipid nanoparticles bearing Oxybenzone: in-vitro and in-vivo evaluation. Gulbake A, Jain A, Khare P, Jain SK, J Microencapsul 2010 27 3 226 233 10.3109/02652040903067844 19622017
19. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles. Maaben S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, Muller BW, Proc Int Symp Control Rel Bioact Mater 1993 20 490 491 (Pubitemid 23269705)
20. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Yang SC, Zhu JB, Lu Y, Liang BW, Yang CZ, Pharm Res 1999 16 751 757 10.1023/A:1018888927852 10350020 (Pubitemid 29227107)
21. The current status of solid lipid nanoparticles. Mukherjee S, Ray S, Thakur RS, Pharmabit, XV 2007 1 53 60
22. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Almeida AJ, Runge S, Muller RH, Int J Pharm 1997 149 255 265 10.1016/S0378-5173(97)04885-0 (Pubitemid 27193412)
23. Nucleation, growth and breakage phenomena in agitated wet granulation processes: A review. Iveson SM, Litster JD, Hapgood KP, Ennis BJ, Powder Technol 2001 117 3 39 10.1016/S0032-5910(01)00313-8 (Pubitemid 32454969)